SCHEMBL19849652

SCHEMBL19849652

COC(=O)c1cccc(-c2cccc(C(=O)OC)c2C)c1C

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.53
LMNA P02545 2/20 0.53
PTPRC P08575 1/20 0.53
ALDH1A1 P00352 3/20 0.52
CFTR P13569 1/20 0.52
HSD17B10 Q99714 1/20 0.52
SLC6A3 Q01959 5/20 0.51
SLC6A4 P31645 3/20 0.51
MEN1 O00255 1/20 0.51
MAPT P10636 1/20 0.51
HTT P42858 1/20 0.51
MAPK10 P53779 1/20 0.51
KMT2A Q03164 1/20 0.51
PTK2B Q14289 1/20 0.51
NCOA1 Q15788 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
NPSR1 Q6W5P4 1/20 0.51
NCOA3 Q9Y6Q9 1/20 0.51
POLB P06746 2/20 0.50
KDM4E B2RXH2 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29634134 1.00 TSHR (0.53) TSHRLMNAPTPRCALDH1A1CFTR
SCHEMBL28684512 0.93 PTGER1 (0.52) TSHRLMNAPTPRCALDH1A1CFTR
SCHEMBL13117430 0.91 TSHR (0.59) TSHRLMNAPTPRCALDH1A1CFTR
SCHEMBL20763545 0.89 TSHR (0.59) TSHRPTPRCALDH1A1HSD17B10MEN1
SCHEMBL3511612 0.89 LMNA (0.59) TSHRLMNAPTPRCALDH1A1CFTR
SCHEMBL13117416 0.88 TSHR (0.51) TSHRLMNAPTPRCALDH1A1CFTR
SCHEMBL29918042 0.87 PDCD1 (0.60) TSHRLMNAALDH1A1SLC6A3SLC6A4
SCHEMBL2898209 0.87 MYC (0.54) TSHRLMNAPTPRCALDH1A1CFTR
SCHEMBL5533081 0.87 PDCD1 (0.60) TSHRLMNAALDH1A1SLC6A3SLC6A4
SCHEMBL13117406 0.87 LMNA (0.49) TSHRLMNAPTPRCALDH1A1CFTR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11787766-B2 Compound having PD-L1 inhibitory activity, preparation method therefor and use thereof SHANGHAI ENNOVABIO PHARMACEUTICALS CO., LTD. (CN) 2023-10-17 US disclosed
US-11787766-B2 Compound having PD-L1 inhibitory activity, preparation method therefor and use thereof SHANGHAI ENNOVABIO PHARMACEUTICALS CO., LTD. (CN) 2023-10-17 US disclosed
WO-2023093686-A1 BENZO[C]CINNOLINE SKELETON DIIMIDE LIGAND AND PREPARATION METHOD THEREFOR 中国科学院上海有机化学研究所 2023-06-01 WO disclosed
CN-109195602-B Symmetrical or semi-symmetrical compounds useful as immunomodulators 上海齐鲁制药研究中心有限公司 2022-01-07 CN disclosed
US-20200392083-A1 COMPOUND HAVING PD-L1 INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR AND USE THEREOF SHANGHAI ENNOVABIO PHARMACEUTICALS CO., LTD. (CN) 2020-12-17 US disclosed
EP-3669872-A1 COMPOUND HAVING PD-L1 INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR AND USE THEREOF Shanghai Ennovabio Pharmaceuticals Co., Ltd. (CN) 2020-06-24 EP disclosed
WO-2019034172-A1 COMPOUND HAVING PD-L1 INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR AND USE THEREOF 上海轶诺药业有限公司 2019-02-21 WO disclosed
US-20180065917-A1 IMMUNE CHECKPOINT INHIBITORS, COMPOSITIONS AND METHODS THEREOF POLARIS PHARMACEUTICALS, INC. (JP) 2018-03-08 US disclosed
US-20180065917-A1 IMMUNE CHECKPOINT INHIBITORS, COMPOSITIONS AND METHODS THEREOF POLARIS PHARMACEUTICALS, INC. (JP) 2018-03-08 US disclosed
US-20180065917-A1 IMMUNE CHECKPOINT INHIBITORS, COMPOSITIONS AND METHODS THEREOF POLARIS PHARMACEUTICALS, INC. (JP) 2018-03-08 US disclosed
WO-2018045142-A1 IMMUNE CHECKPOINT INHIBITORS, COMPOSITIONS AND METHODS THEREOF POLARIS PHARMACEUTICALS, INC. (US) 2018-03-08 WO disclosed
WO-2018045142-A1 IMMUNE CHECKPOINT INHIBITORS, COMPOSITIONS AND METHODS THEREOF POLARIS PHARMACEUTICALS, INC. (US) 2018-03-08 WO disclosed
WO-2018026971-A1 SYMMETRIC OR SEMI-SYMMETRIC COMPOUNDS USEFUL AS IMMUNOMODULATORS ARISING INTERNATIONAL, LLC (US) 2018-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180065917-A1 IMMUNE CHECKPOINT INHIBITORS, COMPOSITIONS AND METHODS THEREOF CD274, PDCD1, PDCD1LG2 TSHR 1383/4885LMNA 2724/4885PTPRC 306/4885
US-20200392083-A1 COMPOUND HAVING PD-L1 INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR AND USE THEREOF CD274, PDCD1LG2, PDCD1 TSHR 3072/4885LMNA 862/4885PTPRC 1099/4885
US-11787766-B2 Compound having PD-L1 inhibitory activity, preparation method therefor and use thereof CD274, PDCD1, PDCD1LG2 TSHR 3322/4885LMNA 1616/4885PTPRC 1429/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.